Magrath George has filed a notice to sell shares of Opus Genetics, Inc. This filing, made on November 3, 2026, is significant as it indicates a financial maneuver to cover tax liabilities associated with stock ownership.

Opus Genetics, Inc., a company engaged in pharmaceutical preparations, is based in Durham, North Carolina. The firm operates under the Central Index Key (CIK) 0001228627 and is listed on the NASDAQ. The latest filing is part of a series of transactions by George, who serves as an officer of the company.

The SEC filing details that George plans to sell 28,258 shares of Opus Genetics, with an aggregate market value of approximately $110,183.59. The shares were acquired through a Restricted Stock Unit (RSU) grant that vested on November 1, 2026. The filing notes, "TRADE IS NOT DISCRETIONARY AS SALE IS REQUIRED TO COVER ANY TAX LIABILITY," indicating the urgency of the transaction.

This sale could impact the shareholders of Opus Genetics, as it reflects the financial strategies employed by its officers. The filing also shows that George sold 9,591 shares on October 23, 2026, for gross proceeds of $34,384.00.

As for what’s next, the filing does not specify any upcoming actions or further disclosures related to this transaction.